LGALS3 and type 2 diabetes mellitus: Notably, Galectin-3 levels remain persistently elevated in newly diagnosed T2D patients even after intensive glycemic optimization and EAT volume reduction, suggesting ongoing inflammatory or fibrotic activity independent of glycemia [65].